EurekAlert -- The investigational use of doripenem for the treatment of ventilator-associated pneumonia (VAP) was associated with shorter patient length of stay and reduced hospital resource utilization, according to new data published in the April edition of Clinical Therapeutics. The total number of hospital days and time on mechanical ventilation were significantly shorter for patients treated with doripenem compared to the commonly used imipenem-cilastatin in exploratory analyses from a Phase III pivotal trial evaluating the safety and effectiveness of doripenem in the treatment of VAP.
